洛匹那韦-利托那韦与硼替佐米合用导致肝损伤的回顾性研究 : = Retrospective study on liver injury due to lopinavir-ritonavir combined with bortezomib
目的分析洛匹那韦-利托那韦与硼替佐米合用导致肝损伤的临床特点和预后。方法回顾性分析2014年1月至2016年12月本院收治的AIDS合并多发性骨髓瘤患者的病历资料。对同时服用洛匹那韦-利托那韦和硼替佐米的患者,利用RUCAM量表评价药物与肝损伤之间的相关性,并分析肝损伤发生的类型、严重程度和预后影响因素。结果洛匹那韦-利托那韦与硼替佐米合用导致肝损伤的平均发生时间为(16.33±10.36)d,肝脏生化学指标AST/ALT <1,患者以肝细胞损伤型为主,RUCAM量表评分≥7分(很可能),严重程度为1级(轻度)。停药给予保肝治疗后,ALT下降幅度大于50%的平均时间为(11.26±4.31)d。结论 AIDS合并多发性骨髓瘤的患者在使用洛匹那韦-利托那韦与硼替佐米治疗时,出现的药物性肝损伤以肝细胞损伤型为主,ALT和TBIL的升高程度与预后有关。.
Objective To analyze the clinical characteristics and prognosis of liver injury induced by lopinavirritonavir combined with bortezomib. Methods Medical records of AIDS patients with multiple myeloma treated in our hospital from January, 2014 to December, 2016 were retrospectively analyzed. For patients taking lopinavir-ritonavir and bortezomib simultaneously, the RUCAM scale was used to evaluate the correlation between the drugs and liver injury, and to analyze the severity and prognostic factors for liver injury. Results The average occurrence of liver injury induced by lopinavir-ritonavir combined with bortezomib was(16.33±10.36) days, and liver biochemical parameters AST/ALT < 1. Hepatic cell injury was the main type, and the RUCAM scale scored ≥ 7(most probably), and the severity was grade 1(mild). After stopping the drug use followed by hepatoprotective treatment, the average time for ALT to drop more than 50% was(11.26±4.31) days. Conclusion When AIDS patients with multiple myeloma are treated with combination of lopinavirritonavir with bortezomib, the main drug-induced injury is hepatic cell injury. The degree of AST and TBIL elevation is related to prognosis..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019-11-20 2019 |
|---|---|
| Erschienen: |
2019-11-20 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2019 |
|---|---|
| Enthalten in: |
Zhong nan yao xue - (2019), 11 vom: 20. Nov., Seite 1958-1962 Original Letters: Enthalten in 中南药学 (DE-600)2993699-8 (DE-600)2993699-8 湖南省长沙市 |
| Reihe: |
China Academic Journals (CAJ), E, 医药卫生科技 = Medicine & Public Health |
|---|
| Sprache: |
Chinesisch |
|---|
| Weiterer Titel: |
Retrospective study on liver injury due to lopinavir-ritonavir combined with bortezomib |
|---|
| Beteiligte Personen: |
王延涛 [VerfasserIn] |
|---|
| Links: |
oversea.cnki.net [lizenzpflichtig] |
|---|
| Themen: |
内科学 |
|---|
| Anmerkungen: |
Author info:WANG Yan-tao;XIA Yu-chao;YU Xiao-dong;YANG Xuan;Henan Provincial Hospital;Henan Infectious Hospital |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
CAJ643780637 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CAJ643780637 | ||
| 003 | DE-627 | ||
| 005 | 20230120225944.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230103s2019 cc |||||o 00| ||chi c | ||
| 035 | |a (DE-627)CAJ643780637 | ||
| 035 | |a (SBB-XA)CAJ_ZNYX201911036 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 044 | |c XB-CN | ||
| 084 | |a ASIEN |q DE-1a |2 fid | ||
| 084 | |a R575 |2 clc | ||
| 100 | 0 | |a 王延涛 |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 洛匹那韦-利托那韦与硼替佐米合用导致肝损伤的回顾性研究 |b = Retrospective study on liver injury due to lopinavir-ritonavir combined with bortezomib |
| 246 | 3 | 1 | |a Retrospective study on liver injury due to lopinavir-ritonavir combined with bortezomib |
| 264 | 1 | |c 2019-11-20 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a China Academic Journals (CAJ) |a E |a 医药卫生科技 = Medicine & Public Health | |
| 500 | |a Author info:WANG Yan-tao;XIA Yu-chao;YU Xiao-dong;YANG Xuan;Henan Provincial Hospital;Henan Infectious Hospital | ||
| 520 | |a 目的分析洛匹那韦-利托那韦与硼替佐米合用导致肝损伤的临床特点和预后。方法回顾性分析2014年1月至2016年12月本院收治的AIDS合并多发性骨髓瘤患者的病历资料。对同时服用洛匹那韦-利托那韦和硼替佐米的患者,利用RUCAM量表评价药物与肝损伤之间的相关性,并分析肝损伤发生的类型、严重程度和预后影响因素。结果洛匹那韦-利托那韦与硼替佐米合用导致肝损伤的平均发生时间为(16.33±10.36)d,肝脏生化学指标AST/ALT <1,患者以肝细胞损伤型为主,RUCAM量表评分≥7分(很可能),严重程度为1级(轻度)。停药给予保肝治疗后,ALT下降幅度大于50%的平均时间为(11.26±4.31)d。结论 AIDS合并多发性骨髓瘤的患者在使用洛匹那韦-利托那韦与硼替佐米治疗时,出现的药物性肝损伤以肝细胞损伤型为主,ALT和TBIL的升高程度与预后有关。 | ||
| 520 | |a Objective To analyze the clinical characteristics and prognosis of liver injury induced by lopinavirritonavir combined with bortezomib. Methods Medical records of AIDS patients with multiple myeloma treated in our hospital from January, 2014 to December, 2016 were retrospectively analyzed. For patients taking lopinavir-ritonavir and bortezomib simultaneously, the RUCAM scale was used to evaluate the correlation between the drugs and liver injury, and to analyze the severity and prognostic factors for liver injury. Results The average occurrence of liver injury induced by lopinavir-ritonavir combined with bortezomib was(16.33±10.36) days, and liver biochemical parameters AST/ALT < 1. Hepatic cell injury was the main type, and the RUCAM scale scored ≥ 7(most probably), and the severity was grade 1(mild). After stopping the drug use followed by hepatoprotective treatment, the average time for ALT to drop more than 50% was(11.26±4.31) days. Conclusion When AIDS patients with multiple myeloma are treated with combination of lopinavirritonavir with bortezomib, the main drug-induced injury is hepatic cell injury. The degree of AST and TBIL elevation is related to prognosis. | ||
| 610 | 2 | 4 | |a 河南省省立医院 |
| 610 | 2 | 4 | |a 河南省传染病医院 |
| 650 | 4 | |a 消化系及腹部疾病 | |
| 650 | 4 | |a 内科学 | |
| 650 | 4 | |a 医药、卫生 | |
| 650 | 4 | |a Digestive System Disease | |
| 650 | 4 | |a 医药卫生科技 | |
| 650 | 4 | |a Medicine & Public Health | |
| 650 | 4 | |a 洛匹那韦-利托那韦 | |
| 650 | 4 | |a 硼替佐米 | |
| 650 | 4 | |a 肝损伤 | |
| 650 | 4 | |a 回顾性研究 | |
| 650 | 4 | |a lopinavir-ritonavir | |
| 650 | 4 | |a bortezomib | |
| 650 | 4 | |a liver injury | |
| 650 | 4 | |a retrospective study | |
| 700 | 0 | |a 夏玉朝 |4 oth | |
| 700 | 0 | |a 余孝东 |4 oth | |
| 700 | 0 | |a 杨萱 |4 oth | |
| 773 | 0 | 8 | |6 880-01 |i Enthalten in |t Zhong nan yao xue |d Hu nan sheng chang sha shi, 2003 |g (2019), 11 vom: 20. Nov., Seite 1958-1962 |h Online-Ressource |w (DE-627)CAJ000176656 |w (DE-600)2993699-8 |7 nnns |
| 773 | 1 | 8 | |g year:2019 |g number:11 |g day:20 |g month:11 |g pages:1958-1962 |
| 856 | 4 | 0 | |u http://erf.sbb.spk-berlin.de/han/caj/oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=ZNYX201911036 |x Verlag |y CrossAsia Link |z Deutschlandweit zugänglich |
| 856 | 4 | 0 | |u https://oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=ZNYX201911036 |x Verlag |z lizenzpflichtig |
| 880 | 0 | 8 | |6 773-01/Hans |i Enthalten in |t 中南药学 |d 湖南省长沙市 |h Online-Ressource |w (DE-627)CAJ000176656 |w (DE-600)2993699-8 |7 nnns |
| 912 | |a ZDB-1-CAJ | ||
| 912 | |a GBV_NL_CAJ | ||
| 912 | |a FID-ASIEN | ||
| 912 | |a SSG-OLC-OA3.1 | ||
| 912 | |a SSG-OLC-CAJ | ||
| 936 | u | w | |j 2019 |e 11 |b 20 |c 11 |h 1958-1962 |
| 951 | |a AR | ||
| 952 | |j 2019 |e 11 |b 20 |c 11 |h 1958-1962 | ||
| 980 | |2 11 |1 01 |x 0001 |b 663285410 |c 00 |f 5:FIDXASIA |d --%%-- |e --%%-- |j --%%-- |y k |z 03-01-23 | ||
| 981 | |2 11 |1 01 |x 0001 |r http://erf.sbb.spk-berlin.de/han/caj/oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=ZNYX201911036 | ||